Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisSteven R. Cummings, Claus Christiansen, José Zanchetta et al.|New England Journal of Medicine|2009Cited by 3.4k
Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of AgeDavid Hosking, A.J.P. Yates, Clair E.D. Chilvers et al.|New England Journal of Medicine|1998Cited by 487
Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal WomenPernille Ravn, Claus Christiansen, Giovanni Cizza et al.|Journal of Bone and Mineral Research|1999Cited by 455
Vertebral Fractures: Clinical Importance and ManagementDavid L. Kendler, E. Michael Lewiecki, Douglas C. Bauer et al.|The American Journal of Medicine|2015Cited by 313
Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate<i>Versus</i>Risedronate Over Two YearsSydney Lou Bonnick, Anne E. de Papp, Kenneth G. Saag et al.|The Journal of Clinical Endocrinology & Metabolism|2006Cited by 144